Futura Medical

FDA green lights MED3000 for OTC approval

Update | 14 July 2020

Share this note

Futura Medical’s update on MED3000, its novel treatment for erectile dysfunction (ED), confirms progress is in line with our expectations. The regulatory filings with both the US FDA and European Notified Body are progressing well. Importantly, the FDA has indicated there is a pathway for MED3000 to be launched as an OTC product in the US. This will require an additional, albeit modest, supplementary clinical trial to demonstrate longer term efficacy. More details should be known by the time of H120 results, likely in early-September. Our DCF-based model, using conservative assumptions, values Futura Medical at £153.8m, equivalent to 60.9p a share.

Year-end: December 31201820192020E2021E
Sales (£m)
Adj. PBT (£m)(7.2)(11.1)(4.8)(3.9)
Net Income (£m)(5.9)(8.9)(4.0)(3.9)
Adj. EPS (p)(4.5)(4.4)(1.6)(1.3)
Cash (£m)*
EBITDA (£m)(7.2)(11.1)(4.8)(3.9)
Source: Trinity Delta Note: Adjusted PBT excludes exceptionals, Cash includes short-term investments. *FY21e cash includes assumed additional funding of £5m.
  • MED3000 set to be an OTC product Productive discussions with the FDA have confirmed MED3000 will likely be approvable immediately as an OTC (over-the-counter) medical device, without the need for a prescription-only phase. Importantly, the FDA is comfortable with the quality of the data generated to date and will require only a small six-month clinical study to confirm the efficacy seen in FM57. The patient numbers required have yet to be established; however, we expect these, and hence the cost of the trial, to be modest, with the company and the FDA cooperating on establishing the ‘least burdensome design’ for the study.
  • European regulatory pathway also clear The MED3000 clinical dossier, including the Clinical Study Report (CSR) for FM57 and the Quality Management System (QMS) documentation, has been filed with the European Notified Body for review. Early indications suggest the data is sound and complete, confirming that our expectations of a first approval by Q421 are realistic. To date COVID-19 has not impacted on the timeline, but we are conscious that it remains a consideration.
  • Partnering discussions will now be simpler The direct to OTC pathway for the commercially important US market removes a degree of complexity from partnering discussions. The intricacies of requiring a prescription-only phase would have probably needed separate companies to address each of the prescription-only and subsequent OTC stages. In Europe, MED3000 is expected to be available immediately as an OTC product in those countries, such as the UK, that have established precedents. Some other countries are expected to take longer.
  • Undervalued and relatively low risk We value Futura Medical at £153.8m (60.9p/share) using a risk-adjusted DCF model with conservative assumptions. We shall revisit our assumptions as further regulatory progress is achieved and as the visibility of the commercialisation and partnering strategies improves.


14 July 2020

Market Cap£38.1m
Enterprise Value£26.5m
Shares in issue245.6m
12 month range7.16-47.9p
Free float62%
ExchangeAIM London
Company CodeFUM.L
Corporate clientYes

Company description

Futura Medical is an R&D driven small pharma company, with a novel DermaSys transdermal delivery platform. The lead programme, MED2005, is a topically applied gel that is in Phase III trials for erectile dysfunction (ED). A pain relief gel, TPR100, is awaiting UK approval.


Lala Gregorek
+44 (0) 20 3637 5043

Franc Gregori
+44 (0) 20 3637 5041

Exhibit 1: Summary of financials
Source: Company, Trinity Delta    Note: Adjusted numbers exclude exceptionals. The funding requirement is shown as short-term debt in FY21e, until transaction type, source and size are confirmed.


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2020 Trinity Delta Research Limited. All rights reserved.